Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)

Autor:	Chritopher Venner, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Harminder Paul, Donna E. Reece, Giovanni Piza Rodriguez, Mariela Pantoja, Leonard Minuk, Jean Roy, Kevin W. Song, Christine Chen, Anca Prica, Michael Sebag, Jason Tay, Terrance Comeau, Julie Stakiw, Darell White
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Hematology Newly diagnosed medicine.disease Minimal residual disease Surgery Busulfan/Melphalan Internal medicine medicine Stem cell business Multiple myeloma Lenalidomide medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 15:e51-e52
ISSN:	2152-2650
DOI:	10.1016/j.clml.2015.07.190
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a680d406ea548bd57631b4856d1bd3f2 https://doi.org/10.1016/j.clml.2015.07.190 Zobrazit plný text záznamu Full Text from ScienceDirect